Gala Pharmaceutical, Inc. (GLPH) financial statements (2020 and earlier)

Company profile

Business Address 18881 VON KARMAN AVE.
IRVINE, CA 92612
State of Incorp. NV
Fiscal Year End November 30
SIC 23 - Apparel And Other Finished Products Made From Fabrics And Similar Materials (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
11/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1588112 0
Cash and cash equivalents1168112 0
Short-term investments42     
Inventory, net of allowances, customer advances and progress billings 223 
Inventory 223  
Prepaid expense6942 3  
Other undisclosed current assets 10    
Total current assets:22762137 0
Noncurrent Assets
Property, plant and equipment3546    
Total noncurrent assets:3546    
TOTAL ASSETS:262108137 0
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8235202889
Settlement liabilities64    
Other undisclosed accounts payable and accrued liabilities1835202889
Debt 374225810 
Derivative instruments and hedges, liabilities 453    
Due to related parties 4825025517528
Total current liabilities:8291029234119337
Noncurrent Liabilities
Other undisclosed liabilities1,039103169130  
Total liabilities:1,1211,01446147119337
Stockholders' equity
Stockholders' equity attributable to parent, including:(811)(906)(448)(464)(193)(37)
Preferred stock111   
Common stock923611301196
Additional paid in capital4,2912,4177874737565
Deferred compensation equity(117)(166)    
Accumulated deficit(5,077)(3,219)(1,237)(1,067)(387) 
Other undisclosed stockholders' equity attributable to parent 25   (108)
Stockholders' equity attributable to noncontrolling interest(47)     
Total stockholders' equity:(859)(906)(448)(464)(193)(37)
TOTAL LIABILITIES AND EQUITY:262108137 0

Income statement (P&L) ($ in thousands)

11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
11/30/2013
Revenues5 22  
Revenue, net 22  
Cost of revenue(3)(74)(18)(1)  
Cost of goods and services sold(2) (18)(214)  
Financial services costs(74)    
Gross profit:1(74)(16)1  
Operating expenses(1,718)(798)(168)(616)(89)(36)
Operating loss:(1,717)(872)(184)(615)(89)(36)
Nonoperating expense(189)(1,184)(2)(64)  
Interest and debt expense153(93)(2)(0)  
Loss from continuing operations before income taxes:(1,754)(2,149)(188)(680)(89)(36)
Income tax expense    (95) 
Loss before gain (loss) on sale of properties:(1,754)(2,149)(188)(680)(184)(36)
Other undisclosed net loss(153)     
Net loss:(1,906)(2,149)(188)(680)(184)(36)
Net income attributable to noncontrolling interest47     
Other undisclosed net income (loss) attributable to parent 167180(95) 
Net loss available to common stockholders, diluted:(1,859)(1,982)(170)(679)(279)(36)

Comprehensive Income ($ in thousands)

11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
11/30/2013
Net loss:(1,906)(2,149)(188)(680)(184)(36)
Comprehensive loss:(1,906)(2,149)(188)(680)(184)(36)
Comprehensive income, net of tax, attributable to noncontrolling interest47     
Comprehensive loss, net of tax, attributable to parent:(1,859)(2,149)(188)(680)(184)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: